ARCHIVES

Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

Hyperthermia Offers Prospects For Major Treatment Advance, Investigators Says

March 11, 1977

Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals

September 25, 1998

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

Sponsors Withdraw Indications for Iressa, Celebrex

February 11, 2011

Carlson Named NCCN Chief Executive

September 28, 2012

NCI 1980s Challenge: Matching Schientific Priorities With Resources, DeVita Says At Swearing-In

August 15, 1980